Suppr超能文献

现状与未来:肥胖症的药物治疗

Present and future: pharmacologic treatment of obesity.

作者信息

Glandt Mariela, Raz Itamar

机构信息

Department of Endocrinology, Bronx-Lebanon Hospital Center, Bronx, NY 10457, USA.

出版信息

J Obes. 2011;2011:636181. doi: 10.1155/2011/636181. Epub 2011 Feb 8.

Abstract

Obesity now presents one of the biggest health problems of our times. Diet and exercise are best for both prevention and treatment; unfortunately, both require much discipline and are difficult to maintain. Medications offer a possible adjunct, but their effect is modest, they are limited by side effects, and the weight loss lasts only as long as the drug is being taken, since as soon as treatment is stopped, the weight is regained. Sibutramine, a sympathomimetic medication which was available for long-term treatment, is the most recent of the drugs to be withdrawn from the market due to side effects; in this case it was an increased risk of cardiovascular events. This paper reviews those medications which are available for treatment of obesity, including many of those recently taken off the market. It also discusses some of the newer treatments that are currently being investigated.

摘要

肥胖如今已成为我们这个时代最大的健康问题之一。饮食和运动对预防和治疗都最为有效;不幸的是,两者都需要很强的自律性且难以坚持。药物治疗是一种可能的辅助手段,但其效果有限,还受副作用限制,而且体重减轻仅在服药期间持续,因为一旦停止治疗,体重就会反弹。西布曲明是一种曾用于长期治疗的拟交感神经药物,它是因副作用而最近被撤出市场的最新药物;在这种情况下,其副作用是心血管事件风险增加。本文综述了可用于治疗肥胖的药物,包括许多最近已退出市场药物。此外,还讨论了目前正在研究的一些新治疗方法。

相似文献

1
Present and future: pharmacologic treatment of obesity.
J Obes. 2011;2011:636181. doi: 10.1155/2011/636181. Epub 2011 Feb 8.
2
[The pharmacological treatment of obesity: past, present and future].
Orv Hetil. 2012 Mar 11;153(10):363-73. doi: 10.1556/OH.2012.29317.
3
[Pharmacological therapy of obesity].
G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S.
4
Long-term effects of weight-reducing drugs in people with hypertension.
Cochrane Database Syst Rev. 2016 Mar 2;3:CD007654. doi: 10.1002/14651858.CD007654.pub4.
6
Long-term effects of weight-reducing drugs in hypertensive patients.
Cochrane Database Syst Rev. 2013 Mar 28(3):CD007654. doi: 10.1002/14651858.CD007654.pub3.
7
9
Safety of antiobesity drugs.
Ther Adv Drug Saf. 2013 Aug;4(4):171-81. doi: 10.1177/2042098613489721.
10
Modern medical management of obesity: the role of pharmaceutical intervention.
J Am Diet Assoc. 1998 Oct;98(10 Suppl 2):S23-6. doi: 10.1016/s0002-8223(98)00706-8.

引用本文的文献

1
Metabolic Efficacy and Diabetes Remission Predictors Following 'Sleeve Gastrectomy with Loop Duodenojejunal Bypass' Surgery.
J Metab Bariatr Surg. 2020 Dec;9(2):33-41. doi: 10.17476/jmbs.2020.9.2.33. Epub 2020 Dec 31.
2
Phytosterols: Nutritional Health Players in the Management of Obesity and Its Related Disorders.
Antioxidants (Basel). 2020 Dec 12;9(12):1266. doi: 10.3390/antiox9121266.
3
Relationship of estrogen synthesis capacity in the brain with obesity and self-control in men and women.
Proc Natl Acad Sci U S A. 2020 Sep 15;117(37):22962-22966. doi: 10.1073/pnas.2006117117. Epub 2020 Aug 31.
5
Inhibition of intestinal lipases alleviates the adverse effects caused by high-fat diet in Nile tilapia.
Fish Physiol Biochem. 2020 Feb;46(1):111-123. doi: 10.1007/s10695-019-00701-x. Epub 2019 Sep 13.
6
(Yacon) Flour Improves Visceral Adiposity and Metabolic Parameters in High-Fat-Diet-Fed Rats.
J Obes. 2018 Oct 28;2018:5341384. doi: 10.1155/2018/5341384. eCollection 2018.
7
Germinated brown rice ameliorates obesity in high-fat diet induced obese rats.
BMC Complement Altern Med. 2016 May 23;16:140. doi: 10.1186/s12906-016-1116-y.
8
Effect of DHA supplementation in a very low-calorie ketogenic diet in the treatment of obesity: a randomized clinical trial.
Endocrine. 2016 Oct;54(1):111-122. doi: 10.1007/s12020-016-0964-z. Epub 2016 Apr 27.
9
Predictors of short-term diabetes remission after laparoscopic Roux-en-Y gastric bypass.
Obes Surg. 2015 May;25(5):782-7. doi: 10.1007/s11695-014-1477-6.
10
Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity.
Endocrine. 2014 Dec;47(3):793-805. doi: 10.1007/s12020-014-0192-3. Epub 2014 Mar 4.

本文引用的文献

1
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.
N Engl J Med. 2010 Sep 2;363(10):905-17. doi: 10.1056/NEJMoa1003114.
2
Gestational diabetes mellitus and obesity.
Diabetes Care. 2010 May;33(5):e60-5. doi: 10.2337/dc10-zb05.
4
Liraglutide (Victoza) for type 2 diabetes.
Med Lett Drugs Ther. 2010 Apr 5;52(1335):25-7.
6
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
Diabetes Care. 2010 Jun;33(6):1255-61. doi: 10.2337/dc09-1914. Epub 2010 Mar 9.
7
Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
Obesity (Silver Spring). 2010 Sep;18(9):1739-46. doi: 10.1038/oby.2009.478. Epub 2010 Jan 21.
8
Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
Obes Rev. 2010 Nov;11(11):777-91. doi: 10.1111/j.1467-789X.2009.00693.x.
9
Effect of topiramate on acid-base balance: extent, mechanism and effects.
Br J Clin Pharmacol. 2009 Nov;68(5):655-61. doi: 10.1111/j.1365-2125.2009.03521.x.
10
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.
Lancet. 2009 Nov 7;374(9701):1606-16. doi: 10.1016/S0140-6736(09)61375-1. Epub 2009 Oct 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验